



2/11

DLA PIPER US LLP
1200 NINETEENTH STREET, NW
WASHINGTON, DC 20036-2412
TELEPHONE: 202-861-3900
FACSIMILE: 202-223-2085

DOCKET NO.: 9511-114 CONT

COMMISSIONER FOR PATENTS
PO BOX 1450
ALEXANDRIA, VA 22313-1450

Re: Serial No.: 10/693,498
Applicant: Richard J. Bucala, et al.
Filing Date: October 27, 2003
For: THERAPEUTIC USES OF FACTORS WHICH INHIBIT OR
NEUTRALIZE MIF ACTIVITY
Art Unit: 1645
Examiner: James Schultz

SIR:

Attached hereto for filing are the following papers:

Revocation of Power of Attorney and New Power of Attorney (with attached list)

Our check in the amount of \$ -0- is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary extension of time to make the filing of the attached documents timely, please charge or credit the difference to Deposit Account No. 50-1442. Further, if these papers are not considered timely filed, then a request is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

DLA PIPER US LLP

John K. Pike, Ph.D.
Registration No. 41,253



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: SEE ATTACHED LIST
SERIAL NO: SEE ATTACHED LIST
FILING DATE: SEE ATTACHED LIST

ART UNIT:
EXAMINER:

REVOCATION OF POWER OF ATTORNEY AND NEW POWER OF ATTORNEY

COMMISSIONER FOR PATENTS
PO BOX 1450
ALEXANDRIA, VA 22313-1450

SIR:

The undersigned representative of **Cytokine PharmaSciences, Inc.**, owner by virtue of assignment of the attached list of applications and patents, hereby revokes any and all previous Powers of Attorney and appoints T. Daniel Christenbury, Reg. No., 31,750; Dale Lazar, Reg. No. 28,872; James M. Heintz, Reg. No. 41,828; Linda R. Judge, Reg. No. 42,702; John K. Pike, Reg. No. 41,253; Lisa K. Norton, Reg. No. 44,977; Daryl A. Basham, Reg. No. 45,869; Ping Wang, Reg. No. 48,328; and Uchendu O. Anyaso, Reg. No. 51,411 as Assignee's attorneys with full power of substitution and revocation, to prosecute said patent application and patents, receive any Letters Patent and to take any and all other actions with regard to this patent application and any Letters Patent issuing thereon, and request that all correspondence be sent to Patent Group, DLA PIPER US LLP, 1200 Nineteenth Street, N.W., Washington, D.C. 20036-2412.

CERTIFICATION UNDER 37 C.F.R. 3.73(b)

I, the undersigned, certify that I am an individual empowered to act on behalf of **Cytokine PharmaSciences, Inc.**, the assignee of the entire right, title and interest of the above-identified application by virtue of an assignment from the inventor(s). I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of these applications or any patent issuing thereon.

Jan. 2, 2007
Date/Signed

Vidal F. de la Cruz
~~Dennis Willson~~ Vidal F. de la Cruz

President Vice President, Business Development



ATTACHED LIST

U.S. Patents

Patent Number	Date of Patent	Inventor
6,774,227	August 10, 2004	Bucala, et al.
6,998,238	February 14, 2006	Bucala, et al.
6,420,188	July 16, 2002	Bucala, et al.
6,492,428	December 10, 2002	Al-Abed, et al.
6,030,615	February 29, 2000	Bucala, et al.
6,080,407	June 27, 2000	Bucala, et al.
6,645,493	November 11, 2003	Bucala, et al.
6,599,938	July 29, 2003	Al-Abed

U.S. Patent Applications

Application Number	Date Filed	Inventor
10/323,656	December 20, 2002	Baugh, et al.
11/599,443	November 15, 2006	Baugh, et al.
08/243,342	May 16, 1994	Bucala, et al.
10/043,322	January 14, 2002	Abe, et al.
60/260,914	January 12, 2001	Abe, et al.
08/479,092	June 6, 1995	Bucala, et al.
08/479,090	June 6, 1995	Bucala, et al.
60/341,832	December 21, 2001	Baugh, et al.
60/340,956	December 19, 2001	Fingerle-Rowson
60/296,478	June 8, 2001	Al-Abed
60/279,435	March 29, 2001	Bucala, et al.
10/322,685	December 19, 2002	Fingerle-Rowson
60/435,525	December 23, 2002	Plasse, et al.
60/498,659	August 29, 2003	Giroir
10/462,751	June 17, 2003	Bucala, et al.
10/693,498	October 27, 2003	Bucala, et al.
60/556,440	March 26, 2004	Sielecki, et al.
60/547,059	February 25, 2004	Willis, et al.
60/547,056	February 25, 2004	Willis, et al.
60/547,057	February 25, 2004	Willis, et al.
60/547,054	February 25, 2004	Willis, et al.
10/828,240	April 21, 2004	Al-Abed
11/225,124	September 14, 2005	Bucala, et al.
11/231,990	September 22, 2005	Bucala
11/090,128	March 28, 2005	Sieleck-Dzurdz, et al.
10/226,299	August 23, 2002	Bucala, et al.
10/164,630	June 10, 2002	Al-Abed
10/927,494	August 27, 2004	Giroir, et al.